Expression of Chikungunya Virus-like Particles

Abstract

Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus responsible for painful disabling polyarthritis, undergoing re-emergence in the Indian Ocean and the Asian continent [1]. Travelling and changing patterns of vector distribution, and abundance due to climate changes, make CHIKV a global threat without effective control strategies. One approach to reduce the CHIKV burden is the development of a vaccine. Virus-like particles (VLPs) are a safe and highly effective class of subunit vaccines that mimic the overall structure of virus particles. Accordingly, we aim to produce CHIKV VLPs in a baculovirus-insect cell system, well known for allowing high yields of recombinant protein expression, to be used as a vaccine preparation.The ORF coding the CHIKV structural proteins is 3.8 kb long, and therefore there is a chance for generating recombinant baculoviruses with spurious stop codons leading to truncated polyproteins. To minimize this possibility, the CHIKV structural sequence was amplified by RT-PCR as a SacI-NotI fragment, and cloned into the mammalian expression vector pLEXm (a gift from R. Aricescu, Oxford, UK) downstream the strong chick beta actin promoter. Several clones with the correct insert size were obtained and transfected into HEK293T cells using polyethylenimine as the transfection reagent[2]. Five recombinant vectors were shown to express CHIKV proteins by immunofluorescence (IFA) and Western blotting (WB) analyses using a polyclonal serum against CHIKV ( Figure 1A). One clone, with high levels of IFA labelling, coded for a truncated viral polyprotein (WB data), while three others, with a lower IFA signal, originated low levels of viral envelope glycoproteins correctly processed. Cells transfected with clone p67 showed IFA staining and viral glycoprotein pattern on WB similar to cells infected with CHIKV ( Figure 1A compare lanes I and p67). Precipitation of clarified cell culture medium from p67 transfected cells, and from CHIKV infected cells, with PEG 8000 generated pellets with an identical content of viral glycoproteins on WB ( Figure 1B). These results strongly indicate that p67 transfected cells express CHIKV structural proteins that are assembled into VLPs. Transmission electron microscopy analysis of p67 transfected cells (Figure 3) confirmed the assembly of VLPs with a morphology similar to the virus particles produced in CHIKV infected cells (Figure 2). Quite unexpectedly, transfected cells expressing only the CHIKV structural proteins (Figure 3) exhibit cytoplasmic membrane rearrangements similar to the vesicle arrays observed in CHIKV infected cells (Figure 2) and reported as induced by non-structural viral proteins. In conclusion, p67 will be used as a source of CHIKV structural genes for construction of recombinant baculoviruses.

Chikungunya Virus: Emerging Targets and New Opportunities for Medicinal Chemistry

“…50 Other promising CHIKV vaccine candidates that depend on virus-like particles are in the early stages of preclinical development. 51,52 A successful viruslike particle vaccine based on viral structural proteins was tested on non-human primates and was found to produce neutralizing antibodies that protect against viremia after high-dose challenge. When these antibodies were transferred into an immunodeficient host (a mice), the host was protected indicating a passive immunity.…”

“…However, this vaccine candidate is still under evaluation in non-human primates . Other promising CHIKV vaccine candidates that depend on virus-like particles are in the early stages of preclinical development. , A successful virus-like particle vaccine based on viral structural proteins was tested on non-human primates and was found to produce neutralizing antibodies that protect against viremia after high-dose challenge. When these antibodies were transferred into an immunodeficient host (a mice), the host was protected indicating a passive immunity …”

Bioengineering virus‐like particles as vaccines

“…Influenza VLPs are possibly the most studied enveloped VLPs (Kang et al, ), commonly consisting of matrix M1 proteins and with glycoprotein hemagglutinin (HA) and/or neuraminidase (NA) embedded in the lipid bilayer. Human immunodeficiency virus (HIV) VLPs (Buonaguro et al, ) and Ebola virus VLPs (Warfield and Aman, ) have also been well reported, with recent attention on VLPs of Chikungunya virus (Metz et al, ; Velez et al, ) and Nipah virus (Walpita et al, ).…”

Expressão da glicoproteína G (RVGP) e proteína de matriz (M) do vírus da raiva utilizando baculovírus recombinante

“…AMAN, 2011) foram bem relatadas, com atenção recente às VLPs do vírus Chikungunya(VELEZ et al, 2012;METZ et al, 2013).…”